Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

Real-time intraoperative guidance is essential during oncological surgery for complete and
safe tumour resection. Fluorescence imaging in the near-infrared spectrum has shown …

The concept of engineering robust protein scaffolds for novel binding functions emerged 20
years ago, one decade after the advent of recombinant antibody technology. Early examples …

131I-GMIB-anti-human epidermal growth factor receptor type 2 (HER2)-VHH1 is a targeted
radionuclide theranostic agent directed at HER2-expressing cancers. VHH1 is a single …

Antibody fragments for which the sequence is available are suitable for straightforward
engineering and expression in both eukaryotic and prokaryotic systems. When produced as …

Radionuclide molecular imaging of human epidermal growth factor receptor type 2 (HER2)
expression may help to stratify breast and gastroesophageal cancer patients for HER2 …

Targeted therapy and immunotherapy have become mainstream in cancer treatment.
However, only patient subsets benefit from these expensive therapies, and often responses …

Affibody molecules are small (58 amino acids) engineered scaffold proteins that can be
selected to bind to a large variety of proteins with a high affinity. Their small size and high …

The targeted delivery of radionuclides to tumours holds great promise for diagnosis and
treatment of malignant neoplasms. The development of scaffold proteins has significantly …

Radionuclide molecular imaging of human epidermal growth factor receptor type 2 (HER2)
expression may enable a noninvasive discrimination between HER2-positive and HER2 …